论文部分内容阅读
应用ＰＣＲ定量分析技术对１０４例肺癌患者的ＭＤＲ１基因进行了前瞻性研究，结果发现，初治患者６９％（５５／８０）有ＭＤＲ１基因表达增高，而经过治疗的患者１００％（２４／２４）有ＭＤＲ１基因表达增高，其中小细胞肺癌（ＳＣＬＣ）的增高有显著意义（Ｐ＜０．０１），在没有经过治疗的患者，２１％（１８／８０）ＭＤＲ１表达量处于高水平，而经过治疗的患者，７５％（１８／２４）ＭＤＲ１表达量较高（Ｐ＜０．０１）。ＭＤＲ１基因高表达的患者化疗有效率明显低于ＭＤＲ１不表达或低表达的患者，其中以ＳＣＬＣ患者最为明显（Ｐ＜０．０１）。结果表明，检测肺癌患者尤其是ＳＣＬＣ患者的ＭＤＲ１基因的表达情况，对临床指导化疗非常重要。
A prospective study of MDR1 gene in 104 patients with lung cancer using PCR quantitative analysis technique found that 69% (55/80) of the untreated patients had increased MDR1 gene expression, compared with 100% (24/24) of treated patients. There was an increase in MDR1 gene expression, with a significant increase in small cell lung cancer (SCLC) (P<0.01). In untreated patients, 21% (18/80) MDR1 expression levels were high and treated. In patients, 75% (18/24) of MDR1 expression was higher (P<0.01). The effective rate of chemotherapy in patients with high expression of MDR1 gene was significantly lower than that in MDR1 patients with no expression or low expression, especially in patients with SCLC (P<0.01). The results show that the detection of MDR1 gene expression in lung cancer patients, especially SCLC patients, is very important for clinical guidance of chemotherapy.